user

NK cell levels predict disease activity in patients with Multiple Sclerosis on Ocrelizumab/Rituximab therapy

被引：0
|
作者：
Dal Bello, Simone [1 ]
Lorenzut, Simone [2 ]
Saccomano, Emma [3 ]
Tereshko, Yan [1 ]
Cargnelutti, Daniela [2 ]
Cutuli, Daniela [2 ]
Gigli, Gian Luigi [3 ]
Valente, Mariarosaria [1 ,3 ]
机构：
[1] Hosp Santa Maria Misericordia, Clin Neurol, Udine, Italy
[2] Hosp Santa Maria Misericordia, Neurol, Udine, Italy
[3] Univ Udine, Dipartiment Med, Dipartimento Area Med, Univ Fruil, Udine, Italy
来源：
MULTIPLE SCLEROSIS JOURNAL | 2023年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P1483/2062
引用
收藏
页码：944 / 945
页数：2
相关论文
共 50 条
  • [1] NK Cell Levels Correlate with Disease Activity in Patients with Multiple Sclerosis on Ocrelizumab/Rituximab Therapy
    Dal Bello, Simone
    Lorenzut, Simone
    Saccomano, Emma
    Tereshko, Yan
    Gigli, Gian Luigi
    Pucillo, Carlo Ennio
    Valente, Mariarosaria
    PHARMACEUTICALS, 2024, 17 (02)
  • [2] The Effect of Ocrelizumab Therapy on Immunoglobulin Levels in Patients with Multiple Sclerosis
    Tran, Vincent
    Miller, Paul
    Olson, Jill
    Miller, Tamara
    Miravalle, Augusto
    NEUROLOGY, 2019, 92 (15)
  • [3] The Effect of Ocrelizumab Therapy on Immunoglobulin Levels in Patients with Multiple Sclerosis
    Tran, Vincent
    Miller, Paul
    Olson, Jill
    Miller, Tamara A.
    Miravalle, Augusto
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 71 - 71
  • [4] Effects of ocrelizumab on NK cell activation in Relapsing Multiple Sclerosis
    Abbadessa, Gianmarco
    Bruzzaniti, Sara
    Miele, Giuseppina
    Piemonte, Erica
    Lepore, Maria Teresa
    Signoriello, Elisabetta
    Lus, Giacomo
    Matarese, Giuseppe
    Galgani, Mario
    Bonavita, Simona
    NEUROLOGY, 2023, 100 (17)
  • [5] The efficacy of ocrelizumab versus rituximab in treating patients with multiple sclerosis
    Shalaby, Nevin
    Abdul-Rahman, Ahmed
    Hegazy, Mohamed
    Merghany, Nahla
    Mounir, Nesma
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 600 - 601
  • [6] Effect of ocrelizumab on T cells and NK cells in patients with Multiple Sclerosis
    Gierlich, Philipp
    Zimmermann, Lena
    Schuhmann, Michael
    Haarmann, Axel
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 812 - 813
  • [7] Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis - No
    Wallin, Mitchell T.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (09) : 1159 - 1161
  • [8] Assessment of ocrelizumab impact on neurofilament levels in multiple sclerosis patients
    Maier, Smaranda
    Hutanu, Adina
    Barcutean, Laura
    Sarmasan, Emanuela
    Balasa, Rodica
    REVISTA ROMANA DE MEDICINA DE LABORATOR, 2024, 32 (03): : 245 - 254
  • [9] The recurrence of disease activity after ocrelizumab discontinuation in multiple sclerosis
    Coerver, E.
    Schoof, L.
    Hogenboom, L.
    Wessels, M.
    van Ruyven, P.
    van Samkar, A.
    Mostert, J.
    van Kempen, Z.
    van Oosten, B. W.
    Wokke, B. H.
    Tallantyre, E.
    Myhr, K. M.
    Torkildsen, O.
    Killestein, J.
    Smets, I.
    Strijbis, E.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2024, 91
  • [10] Ocrelizumab: a B-cell depleting therapy for multiple sclerosis
    Jakimovski, Dejan
    Weinstock-Guttman, Bianca
    Ramanathan, Murali
    Kolb, Channa
    Hojnacki, David
    Minagar, Alireza
    Zivadinov, Robert
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2017, 17 (09) : 1163 - 1172
12345